Search
Omega-6 fatty acids
go.drugbank.com/drugs/DB13168InvestigationalNutraceuticalCells involved in the inflammatory response are typically rich in the n-6 fatty acid arachidonic acid, as generally, eicosanoids derived from n-6 PUFA are pro-inflammatory. … Omega-6 fatty acids are polyunsaturated fatty acids with a final carbon-carbon double bond in the n-6 position, that is, the sixth bond, counting from the methyl end.
Synonyms: n-6 fatty acidscryopreserved human liver cells
go.drugbank.com/drugs/DB05852ExperimentalVesta Therapeutics is a privately held company developing cell therapeutics for liver repair and regeneration. … The Company's technology is centered on the isolation, expansion, and cryopreservation of liver cells (human hepatocytes) obtained from organ donor livers that are not suitable for whole organ transplantation
Alferminogene tadenovec
go.drugbank.com/drugs/DB05306InvestigationalAlferminogene tadenovec, Cardium’s lead product candidate, is being developed for the potential treatment of myocardial ischemia that gives rise to angina symptoms associated with coronary heart disease
Bambuterol
go.drugbank.com/drugs/DB01408InvestigationalBambuterol is a long acting beta-adrenoceptor agonist used in the treatment of asthma. It is a prodrug of terbutaline.
Arundic acid
go.drugbank.com/drugs/DB05343InvestigationalArundic acid has been investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Jojoba oil
go.drugbank.com/drugs/DB14252ApprovedJojoba oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Scutellaria lateriflora
go.drugbank.com/drugs/DB14339ApprovedScutellaria lateriflora is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Inosine pranobex
go.drugbank.com/drugs/DB13156ApprovedInosine pranobex (Isoprinosine or Methisoprinol) is a combination of inosine, acetamidobenzoic acid, and dimethylaminoisopropanol used as an antiviral drug.
Drinabant
go.drugbank.com/drugs/DB05750InvestigationalIt is currently developed in obesity and its associated comorbidities. AVE-1625 is also being developed for the treatment of Alzheimer disease. … AVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant.
FP0011
go.drugbank.com/drugs/DB05090ExperimentalFP0011 is a small molecule antiglutamatergic compound with symptomatic and disease modifying effects in a variety of neurological disorders (amyotrophic lateral sclerosis and Parkinson's disease). … It acts on the presynaptic regulation of glutamate and shows strong neuroprotective properties.